The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.

Original title: “BioMarin acquires experimental drug for rare bone disorder in $275M deal”

Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.

Original title: “Leo Pharma buys rare skin disease drug in $435M deal”

The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.

Original title: “Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars”

With demand for pharma services historically lagging changes in biotech funding, analysts expect CDMOs to experience an uptick in activity in late 2026 or early 2027.

Original title: “Rebounding biotech funds expected to spur CDMO growth within year”

A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.

Original title: “Amylyx’s bet on a GLP-1 blocker pays off”

With a small patient population, ... for clinical trials to manufacturing and ensuring therapy accessibility. “The decision to launch such projects is therefore evaluated not only in terms of potential profitability, but also in terms of the medical significance of the development and the potential to change existing treatment paradigms,” the company explained. When choosing a direction, Biocad analyses a combination of factors: unmet patient need, disease characteristics, ... With a small patient population, development requires significant investment, lengthy research and the creation of complex infrastructure – from diagnostics and patient recruitment for clinical trials to manufacturing and ensuring therapy accessibility. “The decision to launch such projects is therefore evaluated not only in terms of potential profitability, but also in terms of the medical significance of the development and the potential to change existing treatment paradigms,” the company explained. When choosing a direction, Biocad analyses a combination of factors: unmet patient need, disease characteristics, existing treatment standards, scientific data on the potential target, and the feasibility of confirming the new approach’s efficacy in clinical trials. The rare disease market has long been the preserve of global pharma giants, but that is changing. Russian companies are now developing and manufacturing. Practice GxP News. We hope that in the near future we will be able to make a greater contribution to Russian science and pharmaceutical manufacturing, as we expect the foundation’s remit to expand to include experience‑sharing and organising assessments of drug use in clinical practice,” she added. Generium, for example, has been developing orphan drugs from the very start – the company’s history began with their development. “In 2007, Russia introduced a system of drug supply for rare disease patients, providing expensive, often lifelong therapy at state expense. Developing orphan drugs has traditionally been affordable only for large companies: drug development is expensive, clinical trial populations are small, and the market is limited due to the rarity of the diseases. The creation of the state‑run Circle of Kindness foundation – which has improved rare disease diagnosis and become the main buyer of orphan drugs – prompted Russian pharma companies to rethink their business strategies.

Original title: “Why Russian drugmakers are betting on rare diseases despite uncertain returns | Practice | GxP News”

Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

Original title: “FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax”

New alliance aims to accelerate development of future medicines

Original title: “Novo Nordisk and AWS form AI partnership to speed drug discovery”

Despite ranking among the world’s top scientific producers, Italy has struggled to turn research into startups. Now, stronger tech transfer offices, private capital and returning scientists are pushing the country toward a more mature innovation economy.

Original title: “Italian biotech gains momentum as VC funding, tech transfer environment improve”

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $30,000,000, for Federal Fiscal Year 2026 funding to Zambia's University Teaching Hospital (UTH), subject to availability of funds. Funding amounts for years 2-5 will be set at continuation. The award is expected to improve HIV and TB clinical and laboratory service delivery at referral level hospitals and provincial- level referral faciliti

Original title: “Notice of Award of a Sole Source Cooperative Agreement To Fund University Teaching Hospital in Zambia”